Brief: Veracyte Q2 Revenue USD 150.3 Million Vs. IBES Estimate USD 144.6 Million
30/07/2026 21:06
BRIEF-Veracyte Q2 Revenue USD 150.3 Million Vs. IBES Estimate USD 144.6 Million Jul 30 (Reuters) - Veracyte Q2 net income USD 25.5 million.
- Q2 gross margin 72%
- Q2 adjusted operating expenses USD 70 million
- outlook FY revenue USD 590-596 million vs. IBES estimate USD 586.4 million
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina